BMK
NEUTRALBenchmark Holdings Provides Update on Strategy and Return of Capital
The aquaculture biotechnology company announces an update on its strategic direction and plans to return capital to shareholders.
Benchmark Holdings
18.80GBX
6.21%
Market Cap
155.94M
Volume
20
0% of avg
P/E Ratio
0.09
EPS (TTM)
2.14
Beta
0.43
Day Range
0.00p - 0.00p
52 Week Range
0.00p18.80p48.00p
18.80p
Upcoming Events
Mid-September 2025
Maturity of NOK 750m unsecured green bond
High Impact Event
30 September 2025
End of FY25 financial year
BMK
NEUTRALBenchmark Holdings Completes Bond Redemption
The retailer has completed the redemption of its outstanding senior secured bonds.
BMK
NEUTRALBenchmark Holdings Exercises Call Option to Redeem Bonds
The company has notified bondholders that it will exercise a call option to redeem all outstanding bonds under its senior unsecured bond issue.
BMK
GOODBenchmark Completes Disposal of Genetics Business for £260 Million
The aquaculture biotechnology company has completed the sale of its genetics business for £260 million, boosting its cash position and allowing it to focus on core operations.
BMK
NEUTRALBenchmark Holdings Reports Q1 Results - Transition Underway
The aquaculture biotechnology company reports mixed Q1 results, with revenues and profits down but progress on strategic transition.
BMK
NEUTRALBenchmark Holdings Announces Annual General Meeting Date
The aquaculture health, nutrition and genetics business announces the date for its upcoming Annual General Meeting.
BMK
NEUTRALBenchmark Holdings Announces Q1 Results Date
The aquaculture biotechnology company announces the date for its Q1 results release and associated investor presentations.
BMK
NEUTRALBenchmark Holdings Publishes Annual Report
Aquaculture health, nutrition and genetics business publishes annual report.
BMK
NEUTRALBenchmark Holdings Appoints New Chairman
The consumer goods company has appointed a new Chairman, with the previous Chairman retiring after serving for six years.
BMK
BADBenchmark Holdings Reports Challenging Q4 and Full Year 2024 Results
The aquaculture biotechnology firm faced headwinds in Q4, with mixed segment performance. Restructuring efforts and market challenges led to revenue declines and increased operating losses.